Rapport Therapeutics, Inc. (NASDAQ:RAPP) Stock Has Consensus Target Price of $66.60 According to Brokerages

Rapport Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is broadly bullish: Fifteen brokerages give Rapport Therapeutics an average “Buy” rating, with a consensus 12-month price target of $66.60. Recent targets include $86 from Raymond James and $89 from BTIG.
  • RAP-219 produced positive Phase 2 results in bipolar mania, meeting both primary and secondary endpoints, and Rapport plans to advance the drug toward Phase 3. Analysts see potential blockbuster sales, though some cautioned that the statistical significance was narrow and further development carries substantial cost and regulatory risk.
  • The company remains loss-making and insiders have been selling shares: Rapport missed its latest quarterly EPS estimate, reporting a loss of $1.19 per share versus the expected $1.12 loss, while insiders sold 97,976 shares worth about $4.4 million over the past 90 days.
  • Five stocks we like better than Rapport Therapeutics.

Shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) have been assigned an average rating of "Buy" from the fifteen brokerages that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, twelve have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $66.60.

A number of research firms have recently issued reports on RAPP. Wolfe Research began coverage on shares of Rapport Therapeutics in a research note on Thursday, October 15th. They set an "outperform" rating and a $50.00 price objective on the stock. Wall Street Zen downgraded shares of Rapport Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 8th. Citigroup restated an "outperform" rating on shares of Rapport Therapeutics in a report on Tuesday. Raymond James Financial reaffirmed a "strong-buy" rating and set a $86.00 target price on shares of Rapport Therapeutics in a research report on Tuesday. Finally, TD Cowen reiterated a "buy" rating on shares of Rapport Therapeutics in a report on Tuesday.

View Our Latest Stock Report on Rapport Therapeutics

Rapport Therapeutics Price Performance

RAPP stock opened at $29.37 on Wednesday. Rapport Therapeutics has a 1-year low of $23.75 and a 1-year high of $52.93. The business has a fifty day moving average price of $40.31 and a 200-day moving average price of $39.13. The stock has a market capitalization of $1.41 billion, a P/E ratio of -9.66 and a beta of 1.22.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.19) earnings per share for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.07). As a group, analysts anticipate that Rapport Therapeutics will post -4.09 earnings per share for the current year.

Rapport Therapeutics News Roundup

Here are the key news stories impacting Rapport Therapeutics this week:

Insider Buying and Selling at Rapport Therapeutics

In other Rapport Therapeutics news, CEO Abraham Ceesay sold 28,958 shares of the company's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $48.01, for a total transaction of $1,390,273.58. Following the transaction, the chief executive officer owned 486,108 shares in the company, valued at approximately $23,338,045.08. This represents a 5.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Cheryl Gault sold 10,000 shares of the company's stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $33.19, for a total value of $331,900.00. Following the completion of the transaction, the chief operating officer directly owned 139,914 shares in the company, valued at approximately $4,643,745.66. The trade was a 6.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 97,976 shares of company stock worth $4,420,349 over the last ninety days. Corporate insiders own 12.48% of the company's stock.

Institutional Trading of Rapport Therapeutics

Hedge funds have recently modified their holdings of the stock. Algert Global LLC acquired a new stake in Rapport Therapeutics during the second quarter worth about $9,327,000. Johnson & Johnson acquired a new position in Rapport Therapeutics in the 2nd quarter valued at about $74,360,823. Legal & General Group Plc acquired a new position in Rapport Therapeutics in the 2nd quarter valued at about $940,000. Walleye Capital LLC purchased a new stake in shares of Rapport Therapeutics in the 2nd quarter valued at approximately $4,257,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Rapport Therapeutics in the 2nd quarter valued at approximately $3,426,000.

About Rapport Therapeutics

(Get Free Report)

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company's approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport's lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.

Further Reading

Analyst Recommendations for Rapport Therapeutics (NASDAQ:RAPP)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Rapport Therapeutics Right Now?

Before you consider Rapport Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.

While Rapport Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines